The Supreme Court on Monday sought Health Ministry's response on allegations of adulteration of drugs manufactured by Ranbaxy Laboratories.
A Public Interest Litigation (PIL) filed by advocate M L Sharma, has sought the shutting down the three plants, located in Himachal Pradesh, Madhya Pradesh and New Delhi on charges of adulteration.
The apex court has asked the ministry to probe the matter. The Supreme Court has posted the matter for hearing after two weeks.
The Supreme Court had last month directed Ranbaxy to respond to a PIL seeking a probe by the Central Bureau of Investigation (CBI) for allegedly supplying adulterated drugs in the country. The apex court had also asked the government to reply to the plea that sought the court's direction for cancellation of the drug major's licence.
M L Sharma had contended that "Ranbaxy was fined USD 500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs" and sought a CBI probe against the drug maker.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app